Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

Plain-language summary

This study examined the effect of Omega-3 long-chain polyunsaturated fatty acid (LCPUFA) supplementation in preventing retinopathy of prematurity in very low birth weight infants, compared with standard lipid therapy. It included infants born at 30 weeks or earlier or weighing less than 1500 grams at birth. It was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

University of California, San Diego

Intervention

Omegaven, Standard lipids (primarily omega-6 fatty acids)

Start date

3/1/2014

Estimated completion

12/1/2019

Countries

United States

Related genes

Locations

• La Jolla, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Infants born less than or equal to 30 weeks gestation or less than 1500 g at birth

Exclusion Criteria:

* Patients with liver disease as tested by liver function tests (LFTs)
* ≤ 500 grams birthweight